Alcista
$28.44
Precio del escenario
$24.710
+0.902 (+3.65%)Al cierre
OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems.
OrthoPediatrics Corp (KIDS) is a good buy right now due to its current price of $21.95, which is below the analyst price target of $29 set by BTIG. The company has shown significant revenue growth, with Q2 revenue reaching $70.51 million, a 15.4% increase year-over-year, and a gross margin of 74%. However, the main risk is the negative earnings per share (EPS) of -0.30 reported in Q2, which reflects ongoing profitability challenges.
BTIG
$29
2026-08-20
BTIG
2026-08-20
Precio objetivo
$29
Truist
$22
2026-08-05
Truist
2026-08-05
Precio objetivo
$22
Truist
$17
2026-05-01
Truist
2026-05-01
Precio objetivo
$17
Canaccord
$25
2026-04-24
Canaccord
2026-04-24
Precio objetivo
$25
Truist
$20
2026-03-02
Truist
2026-03-02
Precio objetivo
$20
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

National Physical Therapy Month: Innovative Companies Supporting Health

OrthoPediatrics Launches 3P Pediatric Hip System After Successful Limited Rollout

OrthoPediatrics Q2 2026 Earnings Highlights

OrthoPediatrics Q2 Earnings Beat Expectations with Revenue Growth

OrthoPediatrics Partners with OSSIO for Pediatric Fixation Technology
OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
OrthoPediatrics Corp (KIDS) is a good buy right now due to its current price of $21.95, which is below the analyst price target of $29 set by BTIG. The company has shown significant revenue growth, with Q2 revenue reaching $70.51 million, a 15.4% increase year-over-year, and a gross margin of 74%. However, the main risk is the negative earnings per share (EPS) of -0.30 reported in Q2, which reflects ongoing profitability challenges.
4 analysts cover KIDS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 23.00.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.